Nisa Investment Advisors 13F: Adds $3.5M to Amgen (AMGN) Stake
Key Points
- Nisa Investment Advisors boosted its Amgen Inc. holding by 5.2% during the period, bringing its total stake to 167,256 shares worth roughly $70.5 million.
- Amgen recently traded around $445.75, sitting just below its 52-week high of $447.03 and well above its 200-day moving average.
- Several Wall Street firms recently updated their targets for Amgen, with a consensus hold rating from 29 analysts covering the stock.
Since the filing, $AMGN is up 1.9% to date (from the $438.94 close on Oct 20, 2026).
Get Amgen text alerts
We text you when insiders, Congress, analysts or big funds move on $AMGN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Amgen Inc. alert may contain errors. Disclosures
Nisa Investment Advisors increased its holdings in Amgen Inc. AMGN by 8,294 shares during the period, according to a Form 13F filing disclosed on October 20, 2026. The filing showed the fund's total position growing to 167,256 shares with a reported value of $70,500,076. Amgen closed at $438.94 on the day of the filing.
AMGN
Amgen Inc.
Nisa Investment Advisors vs. the S&P 500
Hypothetical returns from Nisa Investment Advisors's disclosed trades, not real profit or advice. How we model this.
What Changed in Nisa Investment Advisors's Amgen Position
Nisa Investment Advisors lifted its stake by 5.2% compared to the previous quarter, adding 8,294 shares to finish the period with 167,256 shares. The increased investment puts the total value of the holding at just over $70.5 million.
Other Institutional Activity in Amgen
Other large investors adjusted their positions in Amgen around the same time. Korea Investment grew its holdings by 113,743 shares, ending with 395,932 shares worth about $140.8 million. Livforsakringsbolaget Skandia, Omsesidigt added 5,980 shares for a total of 77,758 shares valued at about $32.8 million. Annex Advisory Services grew its stake by 98,954 shares, finishing with 111,413 shares worth about $47.0 million. Smead Capital Management trimmed its holdings by 72,737 shares to end with 586,504 shares valued at about $247.2 million. SteelPeak Wealth reduced its position by 68,633 shares, leaving it with 120,157 shares worth about $50.6 million.
Amgen Inc. Stock Up 1.7%
Amgen recently traded around $445.75 on October 22, 2026, sitting up about 1.6% from its $438.94 close on the filing date. The stock trades near its 52-week high of $447.03 and well above its 200-day moving average of $370.53.
Recent Earnings
Amgen reported trailing twelve month revenue of $38.1 billion alongside trailing earnings of $16.10 per share. The next earnings report is scheduled for November 3, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 6.1%. Revenue missed estimates by 1.5%.
-
Profit surprise
EBITDA missed by 45 percent. Operating income missed by 28 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin up 4.6 points. Operating margin up 16.5 points. Positive free cash flow.
Earnings Call Summary
Amgen had a strong first quarter with earnings per share of 5.15 dollars beating expectations of 4.73 dollars. Six key medicines grew sales by 24 percent year over year and now make up 70 percent of total sales. The obesity drug Meritide is advancing well in late-stage testing with new studies showing better tolerance when patients take it less frequently, potentially every eight to twelve weeks instead of weekly injections.
Guidance Amgen raised its 2026 outlook to revenue between 37.1 billion and 38.5 billion dollars, and earnings per share between 21.70 and 23.10 dollars. The company expects its fast-growing medicines like Repatha and Evenity to offset patent losses. Management said capital spending will remain at about 2.6 billion dollars to scale manufacturing for new drug launches.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Amgen pays an annual dividend rate of $10.08 per share, giving the stock a dividend yield of 2.3% with a payout ratio of 60.9%.
Insider Buying and Selling at Amgen Inc.
Company insiders completed three transactions prior to the filing date. Officer Nancy A Grygiel sold 2,970 shares for about $1.2 million on August 6, 2026. Officer Derek Miller sold 3,890 shares for about $1.6 million on the same day. Officer Rachna Khosla sold 3,252 shares valued at about $1.3 million on August 13, 2026.
Analysts Set New Price Targets
Five Wall Street firms updated their views on Amgen ahead of the filing. RBC Capital maintained an Outperform rating with a $430 price target on October 8, 2026. UBS maintained a Buy rating and raised its target to $470 on October 9, 2026. BMO Capital kept a Market Perform rating while adjusting its target to $415 on October 12, 2026. Wells Fargo maintained an Equal-Weight rating with a $430 target on October 12, 2026, and Guggenheim kept a Neutral rating with a $378 target on October 13, 2026. The stock currently holds a consensus hold rating from 29 analysts.
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide, focusing on complex diseases in areas such as oncology, inflammation, and general medicine. Headquartered in Thousand Oaks, California, the company employs over 31,000 people and maintains a large portfolio of biologic treatments used by patients globally.
Bottom Line
Investors are watching for Amgen's upcoming earnings report on November 3, 2026, to gauge ongoing revenue trends and product sales. Institutional filings like this one provide a look at how major investment firms are positioning themselves ahead of those results.
Related Filing Alerts
Source: Nisa Investment Advisors's 13F filing on $AMGN (Oct 20, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts